Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Equity Ratio (2020 - 2025)

Historic Equity Ratio for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to 0.81.

  • Lyell Immunopharma's Equity Ratio fell 587.01% to 0.81 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.81, marking a year-over-year decrease of 587.01%. This contributed to the annual value of 0.78 for FY2024, which is 1068.78% down from last year.
  • Per Lyell Immunopharma's latest filing, its Equity Ratio stood at 0.81 for Q3 2025, which was down 587.01% from 0.78 recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Equity Ratio ranged from a high of 0.89 in Q1 2023 and a low of 0.78 during Q2 2025
  • Its 5-year average for Equity Ratio is 0.84, with a median of 0.84 in 2022.
  • Its Equity Ratio has fluctuated over the past 5 years, first surged by 35606.81% in 2021, then crashed by 1068.78% in 2024.
  • Quarter analysis of 5 years shows Lyell Immunopharma's Equity Ratio stood at 0.82 in 2021, then increased by 7.76% to 0.89 in 2022, then fell by 1.75% to 0.87 in 2023, then fell by 10.69% to 0.78 in 2024, then grew by 3.44% to 0.81 in 2025.
  • Its Equity Ratio stands at 0.81 for Q3 2025, versus 0.78 for Q2 2025 and 0.78 for Q1 2025.